Incyte (INCY) Research & Development (2010 - 2026)
Incyte (INCY) posted Research & Development of $515.9 million for Q1 2026, up 2916.98% on a QoQ basis from $17.1 million in Q4 2025, and up 17.98% year-over-year from $437.3 million in Q1 2025.
Incyte (INCY) Research & Development (2010 - 2026) Analysis & Trends
Incyte's Research & Development history runs 17 years deep, the most recent figure standing at $515.9 million for Q1 2026.
- Quarterly Research & Development rose 17.98% year-over-year to $515.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (down 41.32% YoY) and the FY2025 annual result came in at $2.1 billion, down 21.36% from the prior year.
- Research & Development was $515.9 million for Q1 2026 at Incyte, up from $17.1 million in the prior quarter.
- Across five years, Research & Development topped out at $1.1 billion in Q2 2024 and bottomed at $17.1 million in Q4 2025.
- A 5-year average of $458.4 million and a median of $437.3 million in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development jumped 184.06% — and 2025, when it tumbled 96.33%.
- Incyte's Research & Development stood at $501.4 million in 2022, then fell by 11.34% to $444.5 million in 2023, then rose by 4.85% to $466.0 million in 2024, then tumbled by 96.33% to $17.1 million in 2025, then soared by 2916.98% to $515.9 million in 2026.
- Business Quant data shows INCY's Research & Development at $515.9 million in Q1 2026, $17.1 million in Q4 2025, and $506.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Incyte | 23.47 Bn | 19.46 Bn | 1.17 Bn | 515.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 515.90 Mn |
| Dec 31, 2025 | 17.10 Mn |
| Sep 30, 2025 | 506.58 Mn |
| Jun 30, 2025 | 494.92 Mn |
| Mar 31, 2025 | 437.28 Mn |
| Dec 31, 2024 | 466.03 Mn |
| Sep 30, 2024 | 573.17 Mn |
| Jun 30, 2024 | 1.14 Bn |
| Mar 31, 2024 | 429.26 Mn |
| Dec 31, 2023 | 444.49 Mn |
| Sep 30, 2023 | 375.71 Mn |
| Jun 30, 2023 | 400.75 Mn |
| Mar 31, 2023 | 406.64 Mn |
| Dec 31, 2022 | 501.36 Mn |
| Sep 30, 2022 | 384.01 Mn |
| Jun 30, 2022 | 347.20 Mn |
| Mar 31, 2022 | 353.37 Mn |
| Dec 31, 2021 | 472.83 Mn |
| Sep 30, 2021 | 334.95 Mn |
| Jun 30, 2021 | 343.51 Mn |